English

4D Molecular Therapeutics, Inc.

EDGAR

FDMT Quarterly report (10-Q) · filed 2026-08-13

Annual consolidated revenue for 2025: about USD 85.21M, using the latest reported figures. The previous period, 2024, was about USD 37K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

3.78 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 3781000 USD Source

Operating margin

-2,037.16%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -77025000 USD Source
Revenue: 3781000 USD Source

Operating cash flow

-70 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -138124000 USD Source
Operating Cash Flow: -68125000 USD Source

Cash and cash equivalents: 70.4 million USD 2026-06-30 Source
Exact value

70372000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 55.2 million shares 2026-06-30 Source
Exact value

55214097 shares

Reported share-count change

18.23% · 8.51 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

46700242 shares · 2025-06-30· Source
55214097 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

92 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 90000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 85209000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 119000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 3047000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 3781000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-179 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -56876000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -140109000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -159506000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -68760000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -72936000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-156 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -137633000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -91135000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -109082000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -137633000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -68125000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -138124000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -68125000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

3.42 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Capital expenditure: 2837000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 1059000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 3786000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 2837000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 631000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 697000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 631000 USD · 2025-01-01 – 2025-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-13.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+230,194.6%

Prior period

USD 37,000

2024-01-01 – 2024-12-31
Current period

USD 85.21 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

85209000 − 37000 = 85172000 USD

37000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
85209000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · 4D Molecular Therapeutics, Inc. · 2025-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Year-over-year change in Revenue: 85172000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 85209000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2711615 Filing: 000119312526114075 Input fundies:Revenue: 37000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2713431 Filing: 000119312526114075
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 20.76 million

Prior period

−USD 160.87 million

2024-01-01 – 2024-12-31
Current period

−USD 140.11 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-140109000 − -160868000 = 20759000 USD

-160868000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-140109000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · 4D Molecular Therapeutics, Inc. · 2025-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Year-over-year change in Net income: 20759000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -140109000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2487666 Filing: 000119312526114075 Input fundies:NetIncome: -160868000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2367537 Filing: 000119312526114075
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 25.5 million

Prior period

−USD 134.59 million

2024-01-01 – 2024-12-31
Current period

−USD 109.08 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-109082000 − -134585000 = 25503000 USD

-134585000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-109082000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · 4D Molecular Therapeutics, Inc. · 2025-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Year-over-year change in Operating cash flow: 25503000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -109082000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2570633 Filing: 000119312526114075 Input fundies:OperatingCashFlow: -134585000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2572579 Filing: 000119312526114075
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-85.8%

Prior period

USD 3.79 million

2024-01-01 – 2024-12-31
Current period

USD 536,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

536000 − 3786000 = -3250000 USD

3786000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
536000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · 4D Molecular Therapeutics, Inc. · 2025-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Year-over-year change in Capital expenditure: -3250000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 536000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2585898 Filing: 000119312526114075 Input fundies:CapitalExpenditure: 3786000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2587831 Filing: 000119312526114075
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 85.21 million 100% of revenue
Operating costs Derived USD 244.76 million 287% of revenue
Operating income −USD 159.55 million −187% of revenue
Tax, interest and other Derived −USD 19.44 million −23% of revenue
Net income −USD 140.11 million −164% of revenue

Cash

Operating cash flow −USD 109.08 million −128% of revenue
Capital expenditure USD 536,000 0.6% of revenue
Free cash flow Derived −USD 109.62 million −129% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 827% of revenue.
2020 Operating loss: operating costs were 516% of revenue.
2021 Operating loss: operating costs were 495% of revenue.
2022 Operating loss: operating costs were 3,617% of revenue.
2023 Operating loss: operating costs were 645% of revenue.
2024 Operating loss: operating costs were 507,778% of revenue.
2025 Operating loss: operating costs were 287% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	6986000	57750000 Derived	-50764000	-1458000 Derived	-49306000	-39914000 Derived	Source 2019-01-01 – 2019-12-31: 6986000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -50764000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -49306000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -36711000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 3203000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	13612000	70276000 Derived	-56664000	29000 Derived	-56693000	-51909000 Derived	Source 2020-01-01 – 2020-12-31: 13612000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -56664000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -56693000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -50909000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1000000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	18038000	89371000 Derived	-71333000	-16000 Derived	-71317000	-78244000 Derived	Source 2021-01-01 – 2021-12-31: 18038000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -71333000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -71317000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -69134000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 9110000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	3129000	113161000 Derived	-110032000	-2538000 Derived	-107494000	-98221000 Derived	Source 2022-01-01 – 2022-12-31: 3129000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -110032000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -107494000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -86685000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 11536000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	20723000	133590000 Derived	-112867000	-12030000 Derived	-100837000	-78563000 Derived	Source 2023-01-01 – 2023-12-31: 20723000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -112867000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -100837000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -75792000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 2771000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	37000	187878000 Derived	-187841000	-26973000 Derived	-160868000	-138371000 Derived	Source 2024-01-01 – 2024-12-31: 37000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -187841000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -160868000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -134585000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 3786000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	85209000	244756000 Derived	-159547000	-19438000 Derived	-140109000	-109618000 Derived	Source 2025-01-01 – 2025-12-31: 85209000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -159547000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -140109000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -109082000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 536000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 85.2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	6986000	Revenue: 6986000 Open source
20202020-12-31	Revenue	13612000	Revenue: 13612000 Open source
20212021-12-31	Revenue	18038000	Revenue: 18038000 Open source
20222022-12-31	Revenue	3129000	Revenue: 3129000 Open source
20232023-12-31	Revenue	20723000	Revenue: 20723000 Open source
20242024-12-31	Revenue	37000	Revenue: 37000 Open source
20252025-12-31	Revenue	85209000	Revenue: 85209000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

230,194.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 6986000 Open source
20202020-12-31	Year over year	94.8%	Revenue: 13612000 Open source Revenue: 6986000 Open source
20212021-12-31	Year over year	32.5%	Revenue: 18038000 Open source Revenue: 13612000 Open source
20222022-12-31	Year over year	-82.7%	Revenue: 3129000 Open source Revenue: 18038000 Open source
20232023-12-31	Year over year	562.3%	Revenue: 20723000 Open source Revenue: 3129000 Open source
20242024-12-31	Year over year	-99.8%	Revenue: 37000 Open source Revenue: 20723000 Open source
20252025-12-31	Year over year	230,194.6%	Revenue: 85209000 Open source Revenue: 37000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -187.2% 2025

Net margin -164.4% 2025

Free cash flow margin -128.6% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-726.7%	Operating Income: -50764000 Open source Revenue: 6986000 Open source
20202020-12-31	Operating margin	-416.3%	Operating Income: -56664000 Open source Revenue: 13612000 Open source
20212021-12-31	Operating margin	-395.5%	Operating Income: -71333000 Open source Revenue: 18038000 Open source
20222022-12-31	Operating margin	-3,516.5%	Operating Income: -110032000 Open source Revenue: 3129000 Open source
20232023-12-31	Operating margin	-544.6%	Operating Income: -112867000 Open source Revenue: 20723000 Open source
20242024-12-31	Operating margin	-507,678.4%	Operating Income: -187841000 Open source Revenue: 37000 Open source
20252025-12-31	Operating margin	-187.2%	Operating Income: -159547000 Open source Revenue: 85209000 Open source
20192019-12-31	Net margin	-705.8%	Net Income: -49306000 Open source Revenue: 6986000 Open source
20202020-12-31	Net margin	-416.5%	Net Income: -56693000 Open source Revenue: 13612000 Open source
20212021-12-31	Net margin	-395.4%	Net Income: -71317000 Open source Revenue: 18038000 Open source
20222022-12-31	Net margin	-3,435.4%	Net Income: -107494000 Open source Revenue: 3129000 Open source
20232023-12-31	Net margin	-486.6%	Net Income: -100837000 Open source Revenue: 20723000 Open source
20242024-12-31	Net margin	-434,778.4%	Net Income: -160868000 Open source Revenue: 37000 Open source
20252025-12-31	Net margin	-164.4%	Net Income: -140109000 Open source Revenue: 85209000 Open source
20192019-12-31	Free cash flow margin	-571.3%	Revenue: 6986000 Open source Operating Cash Flow: -36711000 Open source Capital Expenditure: 3203000 Open source
20202020-12-31	Free cash flow margin	-381.3%	Revenue: 13612000 Open source Operating Cash Flow: -50909000 Open source Capital Expenditure: 1000000 Open source
20212021-12-31	Free cash flow margin	-433.8%	Revenue: 18038000 Open source Operating Cash Flow: -69134000 Open source Capital Expenditure: 9110000 Open source
20222022-12-31	Free cash flow margin	-3,139.1%	Revenue: 3129000 Open source Operating Cash Flow: -86685000 Open source Capital Expenditure: 11536000 Open source
20232023-12-31	Free cash flow margin	-379.1%	Revenue: 20723000 Open source Operating Cash Flow: -75792000 Open source Capital Expenditure: 2771000 Open source
20242024-12-31	Free cash flow margin	-373,975.7%	Revenue: 37000 Open source Operating Cash Flow: -134585000 Open source Capital Expenditure: 3786000 Open source
20252025-12-31	Free cash flow margin	-128.6%	Revenue: 85209000 Open source Operating Cash Flow: -109082000 Open source Capital Expenditure: 536000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -109.1M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-36711000	Operating Cash Flow: -36711000 Open source
20202020-12-31	Operating cash flow	-50909000	Operating Cash Flow: -50909000 Open source
20212021-12-31	Operating cash flow	-69134000	Operating Cash Flow: -69134000 Open source
20222022-12-31	Operating cash flow	-86685000	Operating Cash Flow: -86685000 Open source
20232023-12-31	Operating cash flow	-75792000	Operating Cash Flow: -75792000 Open source
20242024-12-31	Operating cash flow	-134585000	Operating Cash Flow: -134585000 Open source
20252025-12-31	Operating cash flow	-109082000	Operating Cash Flow: -109082000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -109.6M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-39914000	Operating Cash Flow: -36711000 Open source Capital Expenditure: 3203000 Open source
20202020-12-31	Free cash flow	-51909000	Operating Cash Flow: -50909000 Open source Capital Expenditure: 1000000 Open source
20212021-12-31	Free cash flow	-78244000	Operating Cash Flow: -69134000 Open source Capital Expenditure: 9110000 Open source
20222022-12-31	Free cash flow	-98221000	Operating Cash Flow: -86685000 Open source Capital Expenditure: 11536000 Open source
20232023-12-31	Free cash flow	-78563000	Operating Cash Flow: -75792000 Open source Capital Expenditure: 2771000 Open source
20242024-12-31	Free cash flow	-138371000	Operating Cash Flow: -134585000 Open source Capital Expenditure: 3786000 Open source
20252025-12-31	Free cash flow	-109618000	Operating Cash Flow: -109082000 Open source Capital Expenditure: 536000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

10.8% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	48.5%	Total Liabilities: 28224000 Open source Total Assets: 58234000 Open source
20202020-12-31	Liabilities / assets	11.1%	Total Liabilities: 31944000 Open source Total Assets: 288331000 Open source
20212021-12-31	Liabilities / assets	9.7%	Total Liabilities: 34380000 Open source Total Assets: 353487000 Open source
20222022-12-31	Liabilities / assets	11.7%	Total Liabilities: 30509000 Open source Total Assets: 261846000 Open source
20232023-12-31	Liabilities / assets	9.4%	Total Liabilities: 32062000 Open source Total Assets: 339891000 Open source
20242024-12-31	Liabilities / assets	8.9%	Total Liabilities: 49778000 Open source Total Assets: 560384000 Open source
20252025-12-31	Liabilities / assets	10.8%	Total Liabilities: 61047000 Open source Total Assets: 566711000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

9.39× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	4.05×	Current Assets: 52508000 Open source Current Liabilities: 12955000 Open source
20202020-12-31	Current assets / current liabilities	16.88×	Current Assets: 282656000 Open source Current Liabilities: 16744000 Open source
20212021-12-31	Current assets / current liabilities	15.69×	Current Assets: 256280000 Open source Current Liabilities: 16338000 Open source
20222022-12-31	Current assets / current liabilities	14.02×	Current Assets: 220511000 Open source Current Liabilities: 15731000 Open source
20232023-12-31	Current assets / current liabilities	15.65×	Current Assets: 296588000 Open source Current Liabilities: 18951000 Open source
20242024-12-31	Current assets / current liabilities	14.92×	Current Assets: 434932000 Open source Current Liabilities: 29149000 Open source
20252025-12-31	Current assets / current liabilities	9.39×	Current Assets: 413134000 Open source Current Liabilities: 43985000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 49.31 million Exact value Exact value: -49306000 USD 2019-01-01 – 2019-12-31: -49306000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 4D Molecular Therapeutics, Inc. · 2019-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Net Income: -49306000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -49306000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000156459021015502/fdmt-10k_20201231.htm#2298817 Filing: 000156459021015502 The citation records this snapshot. The page link may show a newer release later.	−USD 36.71 million Exact value Exact value: -36711000 USD 2019-01-01 – 2019-12-31: -36711000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 4D Molecular Therapeutics, Inc. · 2019-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Operating Cash Flow: -36711000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36711000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000156459021015502/fdmt-10k_20201231.htm#2503934 Filing: 000156459021015502 The citation records this snapshot. The page link may show a newer release later.	USD 3.2 million Exact value Exact value: 3203000 USD 2019-01-01 – 2019-12-31: 3203000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 4D Molecular Therapeutics, Inc. · 2019-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Capital Expenditure: 3203000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3203000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000156459021015502/fdmt-10k_20201231.htm#2511546 Filing: 000156459021015502 The citation records this snapshot. The page link may show a newer release later.	−USD 39.91 million Calculation and evidence -36711000 − 3203000 USD Exact free cash flow: -39914000 USD 2019-01-01 – 2019-12-31: -36711000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 3203000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 4D Molecular Therapeutics, Inc. · 2019-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Free cash flow: -39914000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36711000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000156459021015502/fdmt-10k_20201231.htm#2503934 Filing: 000156459021015502 Input fundies:CapitalExpenditure: 3203000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000156459021015502/fdmt-10k_20201231.htm#2511546 Filing: 000156459021015502 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 56.69 million Exact value Exact value: -56693000 USD 2020-01-01 – 2020-12-31: -56693000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 4D Molecular Therapeutics, Inc. · 2020-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Net Income: -56693000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -56693000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017022004794/fdmt-20211231.htm#2343424 Filing: 000095017022004794 The citation records this snapshot. The page link may show a newer release later.	−USD 50.91 million Exact value Exact value: -50909000 USD 2020-01-01 – 2020-12-31: -50909000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 4D Molecular Therapeutics, Inc. · 2020-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Operating Cash Flow: -50909000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -50909000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017022004794/fdmt-20211231.htm#2558129 Filing: 000095017022004794 The citation records this snapshot. The page link may show a newer release later.	USD 1 million Exact value Exact value: 1000000 USD 2020-01-01 – 2020-12-31: 1000000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 4D Molecular Therapeutics, Inc. · 2020-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Capital Expenditure: 1000000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017022004794/fdmt-20211231.htm#2565070 Filing: 000095017022004794 The citation records this snapshot. The page link may show a newer release later.	−USD 51.91 million Calculation and evidence -50909000 − 1000000 USD Exact free cash flow: -51909000 USD 2020-01-01 – 2020-12-31: -50909000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1000000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 4D Molecular Therapeutics, Inc. · 2020-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Free cash flow: -51909000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -50909000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017022004794/fdmt-20211231.htm#2558129 Filing: 000095017022004794 Input fundies:CapitalExpenditure: 1000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017022004794/fdmt-20211231.htm#2565070 Filing: 000095017022004794 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 71.32 million Exact value Exact value: -71317000 USD 2021-01-01 – 2021-12-31: -71317000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 4D Molecular Therapeutics, Inc. · 2021-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Net Income: -71317000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -71317000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017023008142/fdmt-20221231.htm#2558025 Filing: 000095017023008142 The citation records this snapshot. The page link may show a newer release later.	−USD 69.13 million Exact value Exact value: -69134000 USD 2021-01-01 – 2021-12-31: -69134000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 4D Molecular Therapeutics, Inc. · 2021-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Operating Cash Flow: -69134000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -69134000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017023008142/fdmt-20221231.htm#2738327 Filing: 000095017023008142 The citation records this snapshot. The page link may show a newer release later.	USD 9.11 million Exact value Exact value: 9110000 USD 2021-01-01 – 2021-12-31: 9110000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 4D Molecular Therapeutics, Inc. · 2021-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Capital Expenditure: 9110000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9110000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017023008142/fdmt-20221231.htm#2746171 Filing: 000095017023008142 The citation records this snapshot. The page link may show a newer release later.	−USD 78.24 million Calculation and evidence -69134000 − 9110000 USD Exact free cash flow: -78244000 USD 2021-01-01 – 2021-12-31: -69134000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 9110000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 4D Molecular Therapeutics, Inc. · 2021-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Free cash flow: -78244000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -69134000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017023008142/fdmt-20221231.htm#2738327 Filing: 000095017023008142 Input fundies:CapitalExpenditure: 9110000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017023008142/fdmt-20221231.htm#2746171 Filing: 000095017023008142 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 107.49 million Exact value Exact value: -107494000 USD 2022-01-01 – 2022-12-31: -107494000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 4D Molecular Therapeutics, Inc. · 2022-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Net Income: -107494000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -107494000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017024023183/fdmt-20231231.htm#1935566 Filing: 000095017024023183 The citation records this snapshot. The page link may show a newer release later.	−USD 86.69 million Exact value Exact value: -86685000 USD 2022-01-01 – 2022-12-31: -86685000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 4D Molecular Therapeutics, Inc. · 2022-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Operating Cash Flow: -86685000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -86685000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017024023183/fdmt-20231231.htm#2077805 Filing: 000095017024023183 The citation records this snapshot. The page link may show a newer release later.	USD 11.54 million Exact value Exact value: 11536000 USD 2022-01-01 – 2022-12-31: 11536000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 4D Molecular Therapeutics, Inc. · 2022-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Capital Expenditure: 11536000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11536000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017024023183/fdmt-20231231.htm#2082949 Filing: 000095017024023183 The citation records this snapshot. The page link may show a newer release later.	−USD 98.22 million Calculation and evidence -86685000 − 11536000 USD Exact free cash flow: -98221000 USD 2022-01-01 – 2022-12-31: -86685000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 11536000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 4D Molecular Therapeutics, Inc. · 2022-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Free cash flow: -98221000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -86685000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017024023183/fdmt-20231231.htm#2077805 Filing: 000095017024023183 Input fundies:CapitalExpenditure: 11536000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017024023183/fdmt-20231231.htm#2082949 Filing: 000095017024023183 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 100.84 million Exact value Exact value: -100837000 USD 2023-01-01 – 2023-12-31: -100837000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 4D Molecular Therapeutics, Inc. · 2023-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Net Income: -100837000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -100837000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017025030056/fdmt-20241231.htm#2253722 Filing: 000095017025030056 The citation records this snapshot. The page link may show a newer release later.	−USD 75.79 million Exact value Exact value: -75792000 USD 2023-01-01 – 2023-12-31: -75792000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 4D Molecular Therapeutics, Inc. · 2023-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Operating Cash Flow: -75792000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -75792000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017025030056/fdmt-20241231.htm#2426777 Filing: 000095017025030056 The citation records this snapshot. The page link may show a newer release later.	USD 2.77 million Exact value Exact value: 2771000 USD 2023-01-01 – 2023-12-31: 2771000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 4D Molecular Therapeutics, Inc. · 2023-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Capital Expenditure: 2771000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2771000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017025030056/fdmt-20241231.htm#2433189 Filing: 000095017025030056 The citation records this snapshot. The page link may show a newer release later.	−USD 78.56 million Calculation and evidence -75792000 − 2771000 USD Exact free cash flow: -78563000 USD 2023-01-01 – 2023-12-31: -75792000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 2771000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 4D Molecular Therapeutics, Inc. · 2023-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Free cash flow: -78563000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -75792000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017025030056/fdmt-20241231.htm#2426777 Filing: 000095017025030056 Input fundies:CapitalExpenditure: 2771000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000095017025030056/fdmt-20241231.htm#2433189 Filing: 000095017025030056 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 160.87 million Exact value Exact value: -160868000 USD 2024-01-01 – 2024-12-31: -160868000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 4D Molecular Therapeutics, Inc. · 2024-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Net Income: -160868000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -160868000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2367537 Filing: 000119312526114075 The citation records this snapshot. The page link may show a newer release later.	−USD 134.59 million Exact value Exact value: -134585000 USD 2024-01-01 – 2024-12-31: -134585000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 4D Molecular Therapeutics, Inc. · 2024-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Operating Cash Flow: -134585000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -134585000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2572579 Filing: 000119312526114075 The citation records this snapshot. The page link may show a newer release later.	USD 3.79 million Exact value Exact value: 3786000 USD 2024-01-01 – 2024-12-31: 3786000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 4D Molecular Therapeutics, Inc. · 2024-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Capital Expenditure: 3786000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3786000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2587831 Filing: 000119312526114075 The citation records this snapshot. The page link may show a newer release later.	−USD 138.37 million Calculation and evidence -134585000 − 3786000 USD Exact free cash flow: -138371000 USD 2024-01-01 – 2024-12-31: -134585000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3786000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 4D Molecular Therapeutics, Inc. · 2024-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Free cash flow: -138371000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -134585000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2572579 Filing: 000119312526114075 Input fundies:CapitalExpenditure: 3786000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2587831 Filing: 000119312526114075 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 140.11 million Exact value Exact value: -140109000 USD 2025-01-01 – 2025-12-31: -140109000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 4D Molecular Therapeutics, Inc. · 2025-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Net Income: -140109000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -140109000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2487666 Filing: 000119312526114075 The citation records this snapshot. The page link may show a newer release later.	−USD 109.08 million Exact value Exact value: -109082000 USD 2025-01-01 – 2025-12-31: -109082000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 4D Molecular Therapeutics, Inc. · 2025-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Operating Cash Flow: -109082000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -109082000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2570633 Filing: 000119312526114075 The citation records this snapshot. The page link may show a newer release later.	USD 536,000 Exact value Exact value: 536000 USD 2025-01-01 – 2025-12-31: 536000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 4D Molecular Therapeutics, Inc. · 2025-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Capital Expenditure: 536000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 536000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2585898 Filing: 000119312526114075 The citation records this snapshot. The page link may show a newer release later.	−USD 109.62 million Calculation and evidence -109082000 − 536000 USD Exact free cash flow: -109618000 USD 2025-01-01 – 2025-12-31: -109082000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 536000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 4D Molecular Therapeutics, Inc. · 2025-12-31 4D Molecular Therapeutics, Inc. (edgar:1650648) Free cash flow: -109618000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:38Z Snapshot: 2cbc0a4e4cd5d3e2b850bba5692099ee8290f992fb0a4061bb38e46b875b474d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1650648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -109082000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2570633 Filing: 000119312526114075 Input fundies:CapitalExpenditure: 536000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm#2585898 Filing: 000119312526114075 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

34 filings · 1,696 latest values · 1,696 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001650648, 1650648, FDMT, edgar:1650648

Also known as 4D MOLECULAR THERAPEUTICS, INC., 4D Molecular Therapeutics Inc, 4D Molecular Therapeutics Inc., 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation